TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Kinross Gold (KGC) Stock Tumbling Despite Rising Gold Prices
MARKETS

Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

PRESS RELEASES

Oramed Doses Patients Across Multiple Sites In Phase 3 Oral Insulin Study

PRESS RELEASES

Oramed To Present At H.C. Wainwright BioConnect 2021 Conference

PRESS RELEASES

Oramed Reports Positive First In Human Data From Oral Leptin Study

PRESS RELEASES

Oramed Initiates Phase 2 NASH Trial Of Oral Insulin

PRESS RELEASES

Oramed Initiates Phase 3 Trial Of Oral Insulin

PRESS RELEASES

Nobel Laureate, Oramed SAB Member Prof. Avram Hershko And Oramed CSO Dr. Miriam Kidron To Be Featured On Biotalknology Webinar "Oral Delivery Of Therapeutic Proteins - Oramed Story" On November 18, 2020

PRESS RELEASES

Oramed To Present At H.C. Wainwright 6th Annual Israel Conference

PRESS RELEASES

Oramed To Present Phase 2b Oral Insulin Data At American Association Of Pharmaceutical Scientists 2020 PharmSci 360 Conference

PRESS RELEASES

Oramed CEO Nadav Kidron & Premas Biotech To Host Webinar "The Journey Of Oral Insulin: Oramed Story" On Wednesday October 28, 2020

PRESS RELEASES

Oramed Issues Shareholder Update On Pivotal Phase 3 Oral Insulin Studies: Protocols Submitted To FDA

PRESS RELEASES

Oramed Pharmaceuticals To Present At The European Association For The Study Of Diabetes (EASD) Annual Meeting

PRESS RELEASES

Oramed To Present At H.C. Wainwright Global Investment Conference

PRESS RELEASES

Oramed Reports Positive End Of Phase 2 Meeting With The FDA For Oral Insulin

PRESS RELEASES

Oramed Announces Positive Initial Clinical Trial Results For Treatment Of NASH With Oral Insulin

PRESS RELEASES

Oramed Pharmaceuticals To Present At The 80th American Diabetes Association Scientific Session, To Be Held Virtually This Year In June

PRESS RELEASES

Oramed Patent In Canada Allowed For Oral Delivery Of Proteins

PRESS RELEASES

Oramed Pharmaceuticals Issues CEO Shareholder Letter Providing Business Update Amid COVID-19

PRESS RELEASES

Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA

PRESS RELEASES

Oramed Pharmaceuticals Inc. Prices Public Offering Of Common Stock For Aggregate Proceeds Of $21 Million

PRESS RELEASES

Oramed Pharmaceuticals Inc. Announces Proposed Public Offering Of Common Stock

PRESS RELEASES

Oramed Reports Positive Results In The Final Cohort Of Its Phase 2b Oral Insulin Trial

PRESS RELEASES

Oramed To Present At BIO CEO & Investor Conference

PRESS RELEASES

Oramed Appoints Dr. Julio Rosenstock To Its Scientific Advisory Board

PRESS RELEASES

Oramed Patent In Europe To Be Granted For Oral Delivery Of Proteins